Introduction {#s1}
============

Papillary and follicular thyroid cancers are highly prevalent malignancies arising from transformation of epithelial cells. Mutations in key signaling effectors of the mitogen activated protein kinase (MAPK) pathway, including BRAF and RAS, are found in 70% of thyroid cancers. A recurrent activating mutation in *BRAF, BRAF^V600E^,* is found in 45% of papillary thyroid cancers (PTC), the most common histologic subtype ([@bib37]). Although patients with PTC may be cured with surgery and radioiodine treatment, mutations in BRAF are associated with an increased risk of disease recurrence ([@bib36]). Therefore, it is important to understand the cellular and molecular mechanisms in thyrocytes that lead to malignant transformation by BRAF^V600E^.

Mutations in BRAF have been linked to several mechanisms of malignant transformation. Expression of BRAF^V600E^ has been demonstrated to increase thyrocyte migration and invasion through induction of an epithelial to mesenchymal transition (EMT) in vitro ([@bib2]). Transgenic mouse models demonstrate that expression of BRAF^V600E^ leads to aggressive papillary thyroid carcinomas that progresses to poorly differentiated cancers and demonstrate a loss of sodium iodide symporter expression and a failure to concentrate iodine ([@bib15], [@bib16]; [@bib5]). Yet many human BRAF^V600E^ mutant PTCs are slow growing cancers, that may be clinically stable for years, and identifying these tumors is a key clinical challenge ([@bib10], [@bib11]). While current animal models largely recapitulate aggressive thyroid cancers, there is a need to identify the molecular characteristics that differentiate indolent thyroid cancer from more aggressive subtypes and understand the molecular mechanisms that are involved in progression.

Understanding the temporal consequences of BRAF^V600E^ expression in thyrocytes and thyroid follicles is a key to deciphering the mechanism of malignant transformation. For this reason, we developed a zebrafish model to visualize the consequences of BRAF^V600E^ expression on thyrocyte follicle structure, hormone synthesis, and organ morphogenesis. Expression of BRAF^V600E^ in zebrafish thyrocytes leads to profound disruption of follicle structure and thyroid hormone production, changes that precede an increase in proliferation. Transgenic zebrafish that express BRAF^V600E^ in thyrocytes develop thyroid carcinomas by one year of age with histopathologic hallmarks of human papillary thyroid cancer. Tumors from zebrafish harbor a gene expression signature that stratifies disease recurrence in patients with papillary thyroid carcinoma. We identify an orthologue of human TWIST2, *twist3,* as a key mediator of BRAF^V600E^ induced EMT in thyrocytes. Using CRISPR/Cas9 gene editing we demonstrate that *twist3* loss of function suppresses the effects of BRAF^V600E^ on follicle morphogenesis and hormone production. These studies provide critical insight into the earliest effects of oncogenic BRAF^V600E^ in thyrocytes.

Results {#s2}
=======

Characterization of transgenic zebrafish expressing BRAF^V600E^ in thyrocytes {#s2-1}
-----------------------------------------------------------------------------

In order to investigate the temporal consequences of oncogenic BRAF expression in thyrocytes, we created stable transgenic lines expressing either human BRAF^V600E^ and a TdTomato reporter gene (tg-BRAF^V600E^-TOM) or TdTomato alone (tg-TOM), both under control of a thyroid-specific promoter ([@bib24]) ([Figure 1A](#fig1){ref-type="fig"}). At five days post-fertilization (dpf) control, tg-TOM larvae formed distinct well-organized thyroid follicles composed of TdTomato+ thyrocytes surrounding colloid containing thyroid hormone, positioned in the ventral aspect of the jaw ([Figure 1B](#fig1){ref-type="fig"}), as previously reported ([@bib34]; [@bib25]). In contrast, tg-BRAF^V600E^-TOM larvae exhibited profound defects in thyroid follicle morphogenesis, forming disorganized clusters of thyrocytes ([Figure 1C](#fig1){ref-type="fig"}). This phenotype was followed by live imaging and was highly penetrant.10.7554/eLife.20728.002Figure 1.BRAF^V600E^ expression in thyrocytes disrupts follicle structure.(**A**) Schematic diagram of the constructs used to create transgenic lines, containing a specific zebrafish thyroglobulin promoter (zf tg prom) driving expression of either human BRAF^V600E^ or TdTomato fluorophore. (**B--C**) Brightfield micrographs overlayed on to an epifluorescent micrograph of a live 5 dpf tg-TOM and tg-BRAF^V600E^-TOM larvae. (**D--E**) Representative confocal images of 5 dpf fixed tg-TOM and tg-BRAF^V600E^-TOM larvae immunostained with anti-T4 antibody; white arrows indicate T4-positive follicles. (**F**) Quantification of the total follicle number in tg-TOM and tg-BRAF^V600E^-TOM larvae (n = 20). (**G**) Measurement of follicle diameter in tg-TOM and tg-BRAF^V600E^-TOM (n = 45 and n = 30, respectively). \*\*\*p≤0.001, Student\'s two-tailed *t*-test.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.002](10.7554/eLife.20728.002)10.7554/eLife.20728.003Figure 1---figure supplement 1.Expression of BRAF^V600E^ does not affect proliferation of larval thyrocytes.(**A--B**) Representative confocal images stacks of 5 dpf fixed transgenic tg-TOM and tg-BRAF^V600E^-TOM larvae stained with Sytox Green Nucleic Acid Stain; arrows indicate the nuclei of TdTomato-positive cells. (**C**) Quantification of the total number of thyrocytes (n = 10 for both genotypes). (**D--E**) Representative confocal images of tg-TOM and tg-BRAF^V600E^-TOM larvae incubated with BrdU from 3dpf to 5dpf. Immunofluorescence performed with an anti-BrdU antibody, arrows indicate TdTomato-positive BrdU-positive nuclei. (**F**) Quantification of the TdTomato-positive BrdU-positive thyrocytes (n = 4 and n = 3 for tg-TOM and tg-BRAF^V600E^-TOM, respectively) (**G**) Representative images of 5 dpf tg-TOM and tg-BRAF^V600E^-TOM thyroid obtained using Imaris software. (**H**) Quantification of the thyroid volume (18040 ± 15199 μm^3^ and 14841 ± 6422 μm^3^ for tg-TOM and tg-BRAF^V600E^-TOM). Ns: not significant, two-tailed Student\'s t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.003](10.7554/eLife.20728.003)

To investigate whether expression of BRAF^V600E^ in thyroid follicular cells caused variation in thyroid hormone (T4, thyroxine) production or follicle number, we performed whole mount anti-T4 immunostaining to identify individual T4+ follicles. As expected, at 5 dpf tg-TOM larvae formed an average of five T4+ follicles along the ventral-medial axis ([Figure 1D and F](#fig1){ref-type="fig"}). In contrast, tg-BRAF^V600E^-TOM larvae displayed a significant decrease in the number and size of T4+ follicles ([Figure 1E--G](#fig1){ref-type="fig"}). To examine the effects on proliferation in BRAF^V600E^ thyrocytes, we stained tg-BRAF^V600E^-TOM and tg-TOM with Sytox Green Nucleic Acid Stain and counted the total number thyrocytes at 5 dpf. Total thyrocyte number was comparable between tg-BRAF^V600E^-TOM and tg-TOM control larvae ([Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}). Thyrocyte proliferation was further evaluated by BrdU incorporation into newly synthesized DNA. BrdU-positive TdTomato-positive cell number was not significantly different between tg-BRAF^V600E^-TOM and tg-TOM control larvae ([Figure 1---figure supplement 1D--F](#fig1s1){ref-type="fig"}). Additionally, the total area and volume encompassed by Td-Tomato positive thyroid cells was comparable between tg-BRAF^V600E^-TOM and control larvae ([Figure 1---figure supplement 1G and H](#fig1s1){ref-type="fig"}). These results reveal that expression of BRAF^V600E^ in follicular cells disrupts follicle integrity, resulting in decreased number and size of follicles without altering cell number.

Combined inhibition of BRAF^V600E^ and MEK restores follicular morphology in thyrocytes expressing BRAF^V600E^ {#s2-2}
--------------------------------------------------------------------------------------------------------------

To investigate whether aberrant thyroid follicle morphogenesis in BRAF^V600E^ larvae could be suppressed by inhibition of MAPK signaling, we treated tg-BRAF^V600E^-TOM and tg-TOM embryos with either dabrafenib, a specific inhibitor BRAF^V600E^ ([@bib13]) or selumetinib ([@bib14]), a MEK inhibitor, or the combination of both inhibitors and observed thyroid structure by live imaging. To limit defects caused by inhibition of MAPK signaling on early development, embryos were treated at doses compatible with normal development ([Figure 2A](#fig2){ref-type="fig"}). Vehicle (DMSO) treated tg-BRAF^V600E^-TOM larvae exhibited disorganized follicular structure in contrast to tg-TOM larvae at 5 dpf ([Figure 2B](#fig2){ref-type="fig"}). Treatment with either dabrafenib or selumetinib alone was not sufficient to restore normal thyroid morphogenesis in tg-BRAF^V600E^-TOM larvae. By contrast, combined treatment with both dabrafenib and selumetinib restored normal thyroid follicular structure ([Figure 2B](#fig2){ref-type="fig"}), T4 production ([Figure 2C](#fig2){ref-type="fig"}), and led to a significant increase in the number and size of follicles ([Figure 2D and E](#fig2){ref-type="fig"}). Importantly, inhibition of MAPK signaling in tg-TOM larvae had no overt effects on embryo development or thyroid follicular structure, but was associated with a modest decrease in follicle number, consistent with a proliferative requirement in follicle morphogenesis. Taken together, these results suggest that combined inhibition of MEK and BRAF^V600E^ activity is required to restore normal follicular architecture and thyroid hormone (T4) production in tg-BRAF^V600E^-TOM larvae.10.7554/eLife.20728.004Figure 2.Combined treatment with BRAF and MEK inhibitors suppresses morphologic effects induced by BRAF^V600E^ in thyrocytes and restores normal follicle structure.(**A**) Schematic diagram of experimental scheme and treatment conditions of tg-TOM and tg-BRAF^V600E^-TOM larvae. (**B**) Epifluorescent live images of tg-TOM and tg-BRAF^V600E^-TOM larvae treated with either DMSO (vehicle), 2.5 μM dabrafenib, 10 μM selumetinib, or the combination of 2.5 μM dabrafenib and 10 μM selumetinib. (**C**) Representative confocal images of tg-BRAF^V600E^-TOM larvae treated with either DMSO (vehicle), 2.5 μM dabrafenib, 10 μM selumetinib, or the combination of 2.5 μM dabrafenib and 10 μM selumetinib and subject to immunofluorescence (IF) using anti-T4 antibody. (**D--E**) Quantification of thyroid follicle number (**D**) and follicle diameter (**E**) in tg-BRAF^V600E^-TOM larvae after drug treatment compared to vehicle (DMSO) control. The experiment was performed in triplicate. \*p≤0.05, \*\*p≤0.01, Student\'s two-tailed *t*-test, ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.004](10.7554/eLife.20728.004)

BRAF^V600E^ expression leads to TGF-β and EMT gene expression changes in thyrocytes {#s2-3}
-----------------------------------------------------------------------------------

To dissect the molecular pathways involved in the BRAF^V600E^ follicular phenotype, we performed flow sorting of TdTomato-positive thyrocytes from tg-TOM or tg-BRAF^V600E^-TOM transgenic larvae at 5 dpf and isolated RNA for next-generation sequencing. TdTomato-positive cells accounted for 0.076% and 0.060% of the total cells sorted in tg-TOM and tg-BRAF^V600E^-TOM respectively ([Figure 3A](#fig3){ref-type="fig"}), further confirming that the absolute number of thyrocytes is comparable between control and BRAF^V600E^ transgenic larvae. Gene expression analysis revealed significant, differential gene expression between sorted thyrocytes from tg-TOM and tg-BRAF^V600E^-TOM larvae ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}). Several upregulated genes (*wnt11r, her6, axin2* and *twist3*) in tg-BRAF^V600E^-TOM were validated by qPCR ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). To identify key pathways affected by BRAF^V600E^ expression in thyrocytes, we performed gene set enrichment analysis (GSEA) ([@bib31]). This analysis revealed TGF-β and EMT as the most highly differentially induced pathways in BRAF^V600E^ expressing thyrocytes ([Figure 3C--D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Immunostaining of transgenic zebrafish larvae revealed a loss of E-cadherin staining in tg-BRAF^V600E^-TOM thyrocytes ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). To identify similarities between zebrafish thyroid signatures and human signatures, we investigated whether there is a correlation between BRAF^V600E^-induced signature and a human ERK signature ([@bib27]). We found a significant positive correlation with human ERK signature genes ([Figure 3---figure supplement 1C--E](#fig3s1){ref-type="fig"}), consistent with the activation of a conserved program of gene activation with expression of oncogenic BRAF. These results demonstrate that BRAF^V600E^ expression in thyrocytes induces alterations in thyroid follicle morphogenesis that are accompanied by gene expression changes in TGF-β signaling consistent with EMT.10.7554/eLife.20728.005Figure 3.BRAF^V600E^ expression in thyrocytes leads to transcriptional upregulation in genes associated with EMT and TGF-β signaling.(**A**) Schematic diagram of the FACS-sorting workflow with the experimental plots indicating the percentage of TdTomato-positive cells sorted from tg-TOM and tg-BRAF^V600E^-TOM. (**B**) Heat-map depicting top differentially expressed genes ([Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}) in sorted tg-BRAF^V600E^-TOM compared to tg-TOM. (**C**,**D**) Gene set enrichment plots of TGF-β and EMT signatures from RNAseq performed on sorted thyrocytes from tg-BRAF^V600E^-TOM and tg-TOM larvae (E.S.=0.503, FDR = 0.011, nominal p-val = 0.002 and E.S.=0.344, FDR = 0.035, nominal p-val = 0.0, respectively).**DOI:** [http://dx.doi.org/10.7554/eLife.20728.005](10.7554/eLife.20728.005)10.7554/eLife.20728.006Figure 3---source data 1.Differentially expressed genes (FDR ≤ 0.05, 1.2≤ log~2~FC ≤−1.2) in thyrocytes sorted from tg-BRAF^V600E^-TOM as compared with tg-TOM in larval embryos at 5dpf.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.006](10.7554/eLife.20728.006)10.7554/eLife.20728.007Figure 3---figure supplement 1.Gene expression changes induced by BRAF^V600E^ in larval thyrocytes.(**A**) qPCR analysis of select up-regulated genes; data are represented as fold change of tg-BRAF^V600E^-TOM compared to tg-TOM and are normalized using *gapdh* as a control. (**B**) GSEA hallmark gene sets significantly enriched in tg-BRAF^V600E^-TOM (top 10 signatures, FDR \< 25%, nominal p-value\<5%). (**C**) GSEA enrichment plot of ERK signature using RNAseq data generated from sorted zebrafish thyrocytes as described. (**D**) Heat-map of ERK signature genes (n = 37) differentially expressed in tg-BRAF^V600E^-TOM sorted thyrocytes compared to tg-TOM. (**E**) Validation of differential expression of select ERK signature genes using qPCR, data are normalized using *gapdh* as a control. (**F**) E-cadherin immunostaining in tg-TOM and tg-BRAF^V600E^-TOM larvae at 5dpf.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.007](10.7554/eLife.20728.007)

BRAF^V600E^ expression in thyrocytes induces thyroid cancer in adult zebrafish {#s2-4}
------------------------------------------------------------------------------

In order to examine the effects of prolonged BRAF^V600E^ expression, we performed a detailed histopathologic study of cohorts of transgenic tg-BRAF^V600E^-TOM at 5 and 12 months post-fertilization (mpf). Five mpf tg-BRAF^V600E^-TOM adult animals are characterized by thyroglobulin-positive masses invading adjacent gills and skeletal muscle, features that are not observed in age-matched wild-type tg-TOM animals ([Figure 4C--D](#fig4){ref-type="fig"}). Consistent with constitutive activation of BRAF^V600E^, we observed a marked increase in p-ERK in thyroid tissue dissected from tg-BRAF^V600E^-TOM fish compared to control thyroid tissue from tg-TOM fish ([Figure 4E](#fig4){ref-type="fig"}). However, at this stage, invasive thyrocytes did not harbor nuclear grooves or other cytologic features diagnostic of human papillary thyroid carcinoma. We analyzed a second cohort of tg-BRAF^V600E^-TOM adult animals at 12 mpf and found evidence of progressive disease and histologic and cytological features diagnostic of thyroid carcinoma ([Figure 5](#fig5){ref-type="fig"}), including highly invasive carcinomas with thyrocytes invading skeletal muscle and soft tissue ([Figure 5B](#fig5){ref-type="fig"}). These features were not observed in control tg-TOM animals ([Figure 5B](#fig5){ref-type="fig"}). We also observed multiple specific cytologic features of papillary thyroid carcinoma including nuclear grooves, crowded and overlapping nuclei, and elongated nuclei ([Figure 5C](#fig5){ref-type="fig"}). Other features consistent with aggressive thyroid carcinoma including a desmoplastic stromal reaction (2/14 animals, 14%) were observed ([Figure 5C](#fig5){ref-type="fig"}). These data reveal that persistent expression of BRAF^V600E^ in thyrocytes leads to invasive carcinoma with hallmarks of human PTC in 9/14 animals (64%) at one year.10.7554/eLife.20728.008Figure 4.Analysis of a cohort of transgenic zebrafish expressing BRAF^V600E^ in thyrocytes at 5 months post fertilization.(**A--B**) Photographs and epifluorescent photographs of live five mpf tg-TOM (**A**) and Tg-BRAF^V600E^-TOM fish (**B**) reveals TdTomato-positive tissue. (**C**) Representative H&E and IHC using anti-thyroglobulin antibody of sagittal section of adult fish tg-TOM at five mpf. (**D**) Representative images from three tg-BRAF^V600E^-TOM adult fish at five mpf demonstrating the presence of invasive carcinoma. Top panel, mass of Tg-positive thyroid cells (arrows) invading muscle. Middle panel, thyroid cells invading gill tissue (arrows), inset is 40X. Lower panel, thyroid cells invading subcutaneous fat in the ventral jaw (arrows), inset is 40X. (**E**) Western blot analysis of thyroid obtained from two tg-TOM (control) and four tumors bearing tg-BRAF^V600E^-TOM zebrafish. Western blot analysis was performed in duplicate, a representative blot is shown. (**F**) Quantitative analysis of fold change in pERK/total ERK from (**E**), p\<0.05, Student's t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.008](10.7554/eLife.20728.008)10.7554/eLife.20728.009Figure 5.Adult transgenic fish expressing *BRAF^V600E^* in thyrocytes develop invasive thyroid cancer similar to human PTC.(**A--B**) Representative H&E and IHC staining using anti-thyroglobulin and anti-P-ERK antibodies performed on sagittal sections from control tg-TOM (**A**) and tumor bearing tg-BRAF^V600E^-TOM adult zebrafish at 12 mpf (**B**) (20X magnification). Arrows indicate sites of carcinoma invading skeletal muscle, inset is 40X magnification of skeletal muscle invasion. (**C**) High magnification photomicrographs of H&E-stained sections from tg-BRAF^V600E^-TOM animals. Key diagnostic features of papillary thyroid carcinoma are observed: nuclear grooves (arrows), elongated nuclei (arrows), desmoplastic stromal reaction (asterisk) and crowded nuclei (60X magnification).**DOI:** [http://dx.doi.org/10.7554/eLife.20728.009](10.7554/eLife.20728.009)

Gene expression analysis of zebrafish thyroid carcinoma reveals pathways involved in disease progression and a gene expression signature that is predictive of disease-free survival in human PTC {#s2-5}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To identify molecular pathways involved during progression of BRAF^V600E^-induced thyroid carcinoma, TdTomato-positive thyroid carcinomas were micro-dissected from the ventral jaw at 12 mpf and RNA-seq analysis was performed ([Figure 6A](#fig6){ref-type="fig"}). Transcriptomic analysis revealed significant, differential gene expression between normal thyroid tissue isolated from tg-TOM zebrafish and carcinomas isolated from tg-BRAF^V600E^-TOM animals ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---source data 1](#SD2-data){ref-type="supplementary-material"}). To investigate the signaling pathways altered in zebrafish thyroid carcinomas, we performed GSEA analysis ([Figure 6C](#fig6){ref-type="fig"}). As observed in thyrocytes isolated from larvae, we found persistent upregulation in TGF-β signaling, EMT, and glycolysis gene signatures from thyroid carcinomas isolated from 12 mpf zebrafish ([Figure 6C](#fig6){ref-type="fig"}, highlighted in red). However, in adult thyroid carcinoma we found that the top upregulated gene expression signatures are linked to proliferation and metabolism (MYC, and mTORC1 gene sets, highlighted in green). These results indicate that prolonged expression of BRAF^V600E^ leads to upregulation of gene expression pathways associated with proliferation and regulation of cellular metabolism.10.7554/eLife.20728.010Figure 6.Identification of a gene expression signature from adult zebrafish thyroid carcinomas conserved in human patients with thyroid cancer.(**A**) Schematic diagram of the RNA-seq workflow from adult (12mpf) thyroid tissue. (**B**) Heat-map depicting the top differentially expressed genes in tg-BRAF^V600E^-TOM thyroid tissue compared to tg-TOM thyroid tissue ([Figure 6---source data 1](#SD2-data){ref-type="supplementary-material"}). (**C**) GSEA hallmark gene sets significantly enriched in tg-BRAF^V600E^-TOM. (**D**) Volcano plot depicting differentially expressed genes in tg-BRAF^V600E^-TOM compared to tg-TOM thyroid tissue; a set of 58 genes (blue, FDR ≤ 1 × 10^−6^, FC ≤1.5, ([Figure 6---source data 2](#SD3-data){ref-type="supplementary-material"}) was defined as a signature of BRAF^V600E^ expression in thyroid carcinoma. (**E**) Kaplan-Meier analysis of disease free survival in 496 patients with papillary thyroid cancer stratified by median BRAF^V600E^ gene expression signature identified in (**D**).**DOI:** [http://dx.doi.org/10.7554/eLife.20728.010](10.7554/eLife.20728.010)10.7554/eLife.20728.011Figure 6---source data 1.Differentially expressed genes (FDR ≤ 0.05, 1.2≤ log~2~FC ≤−1.2) in thyroid carcinomas isolated from adult tg-BRAF^V600E^-TOM zebrafish as compared with thyroid tissue from adult tg-TOM zebrafish.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.011](10.7554/eLife.20728.011)10.7554/eLife.20728.012Figure 6---source data 2.BRAF^V600E^ downregulated genes (n = 58 genes; FDR ≤ 1×10^−6^, log~2~FC ≤1.5) identified in adult thyroid carcinomas.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.012](10.7554/eLife.20728.012)

Consistent with some BRAF mouse models of thyroid cancer ([@bib6]) we observed a relatively long latency of tumor development. This led us to hypothesize that thyroid carcinomas arising in zebrafish harbor gene expression changes found in indolent human papillary thyroid cancers. To examine this further, we identified a limited set of genes that are significantly deregulated in zebrafish thyroid carcinomas ([Figure 6D](#fig6){ref-type="fig"}, n = 58 genes highlighted in blue, [Figure 6---source data 2](#SD3-data){ref-type="supplementary-material"}) and we used this as a signature to interrogate a reference cohort of 496 human PTCs annotated with clinical outcomes data ([@bib3]). We find that the gene signature identified in zebrafish stratifies disease-free survival in human patients and identifies patients at significantly lower risk of relapse ([Figure 6E](#fig6){ref-type="fig"}). These data imply that thyroid carcinomas arising in zebrafish are representative of slow growing, relatively indolent BRAF^V600E^-driven PTCs arising in human patients.

Identification of *twist3* as a critical mediator of BRAF^V600E^ in thyrocytes {#s2-6}
------------------------------------------------------------------------------

We performed an in silico screen to identify transcription factors associated with BRAF expression in thyrocytes. Using a reference set of RNAseq data from 496 human PTCs, we performed GSEA iteratively across 1657 transcription factors to identify enrichment with genes induced by BRAF^V600E^ expression in larvae ([Figure 7---source data 1](#SD4-data){ref-type="supplementary-material"}). We find that the key transcriptional regulators of EMT, TWIST2 and SNAI2, are highly correlated with BRAF^V600E^ signature genes ([Figure 7A](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). We confirmed that *Twist3*, an orthologue of TWIST2, was significantly upregulated in BRAF^V600E^ expressing thyrocytes ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These data indicate that Twist transcription factors are upregulated in thyrocytes after BRAF^V600E^ expression and may be responsible for inducing broad gene expression changes linked to disruption of thyroid follicles.10.7554/eLife.20728.013Figure 7.Twist expression is required for BRAF^V600E^ mediated thyroid follicle disruption.(**A**) Results from an in silico screen of transcription factor (n = 1665) expression in human PTC correlated with BRAF^V600E^ gene signature performed by GSEA. Top hits represented in red. (**B**) CrisprVariants analysis of *twist3* gene editing in zebrafish embryos. tg-BRAF^V600E^-TOM embryos were microinjected with rCas9 and either a non-targeting sgRNA or a *twist3*-specific sgRNA. Individual embryos were isolated and a clonal analysis of the *twist3* target locus was performed. Non-targeting embryos (n = 5, grouped) had no evidence of deletions at the *twist3* locus, 21/21 clones were wild-type. *Twist3* targeted embryos (n = 5, one per column) had a range of small indels at the targeting site. (**C**) Representative confocal images of 5 dpf fixed tg-BRAF^V600E^-TOM embryo injected with either non-targeting or *twist3* targeting sgRNA. Anti-T4 immunostaining performed to identify T4-positive (green) follicles. (**D**) Quantification of follicle rescue in embryos injected with a non-targeting versus *twist3* targeting sgRNA in BRAF^V600E^-TOM embryos. Follicle rescue was observed in 0/142 non-targeting sgRNA injected embryos vs. 57/173 (32.9%) of *twist3* sgRNA injected embryos, p\<1.0 × 10^−3^, two-tailed Fisher exact test. (**E**) FACS plot of TdTomato-positive cells isolated from *twist3* sgRNA injected tg-BRAF^V600E^-TOM embryos. (**F**) Alignment of DNA chromatogram from a clone isolated from *twist3* sgRNA injected TOM+ cells harboring a three nucleotide deletion in the *twist3* gene. The *twist3* sgRNA sequence is underlined in red.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.013](10.7554/eLife.20728.013)10.7554/eLife.20728.014Figure 7---source data 1.BRAF^V600E^ upregulated genes (n = 85 genes; FDR ≤ 0.01, FC ≥ 1.5) identified in larval thyrocytes.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.014](10.7554/eLife.20728.014)10.7554/eLife.20728.015Figure 7---figure supplement 1.Validation of gene editing in thyrocytes and identification of a BRAF^V600E^ gene signature.(**A**) Volcano plot depicting differentially expressed genes in tg-BRAF^V600E^-TOM compared to tg-TOM sorted thyrocytes from larvae. Genes significantly upregulated in BRAF^V600E^ thyrocytes are highlighted in blue (n = 85 genes, FDR ≤ 0.01; FC ≥ 1.5, [Figure 7---source data 1](#SD4-data){ref-type="supplementary-material"}). (**B**) T7 mutagenesis assay at the CRISPR target site in the *twist3* gene. The assay was performed on genomic DNA from 1dpf embryos injected with either non-targeting sgRNA or *twist3* targeting sgRNA and rCas9. Cleavage bands indicate cleavage of hetero-duplex DNA consistent with the presence of mutations at the target site. (**C**) Photograph of representative 5dpf embryos injected with either non-targeting sgRNA or twist3 sgRNA and rCas9. No significant morphologic defects are noted.**DOI:** [http://dx.doi.org/10.7554/eLife.20728.015](10.7554/eLife.20728.015)

To determine the functional requirements for Twist transcription factors downstream of BRAF^V600E^ in thyrocytes, we performed CRISPR/Cas9 gene editing. We designed and validated an sgRNA targeting *twist3* in zebrafish embryos. Microinjection of a *twist3* targeted sgRNA in combination with recombinant Cas9 protein leads to specific indels in the *twist3* gene at the target locus, a majority of which are predicted to disrupt protein coding ([Figure 7B](#fig7){ref-type="fig"}). In order to examine thyroid effects, we performed CRISPR/Cas9 gene editing of *twist3* in tg-BRAF^V600E^-TOM larvae. After microinjection of sgRNA targeting *twist3,* we observed rescue of follicle structure and thyroid hormone production in 57/173 (32.9%) embryos ([Figure 7C--D](#fig7){ref-type="fig"}). In contrast, non-targeting sgRNA-injected tg-BRAF^V600E^-TOM embryos exhibit profound defects in follicle structure and thyroid hormone production ([Figure 7C](#fig7){ref-type="fig"}) as previously described. To determine whether the *twist3* gene was edited in thyrocytes, we flow sorted TOM+ thyrocytes from 6dpf larvae ([Figure 7E](#fig7){ref-type="fig"}) injected with twist3 or non-targeting sgRNAs. We isolated gDNA from TOM+ cells and performed a clonal analysis of twist3 gene editing. We identified a deletion in the twist3 gene in 1/12 clones (8.3%) from TOM+ cells isolated from embryos injected with a twist3 targeting sgRNA, and 0/12 clones isolated from TOM+ cells from embryos injected with a non-targeting sgRNA. These data indicate that genetic disruption of *twist3* is sufficient to partially rescue the effects of BRAF^V600E^ on thyroid follicle structure and hormone production.

Discussion {#s3}
==========

Here, we describe the generation and characterization of a novel model of thyroid cancer. We created a transgenic zebrafish expressing BRAF^V600E^ in fluorescently labeled thyrocytes. By following thyrocytes from the earliest stages of specification, we are able to examine the timeline of oncogenic BRAF^V600E ^in vivo where we observe significant disruption of follicle structure and thyroid hormone production. However, thyrocyte number remains normal in larval development. RNAseq analysis from sorted thyrocytes confirms that genes associated with EMT and TGF-β are transcriptionally activated by BRAF^V600E^. These data suggest that BRAF^V600E^ activation of downstream signaling pathways converges on a gene expression program that results in loss of epithelial organization without affecting proliferation. Pharmacologic inhibition of BRAF/MEK suppresses the morphologic alterations and restores normal thyroid follicle structure. Prolonged expression of oncogenic BRAF^V600E^ leads to slow growing thyroid carcinoma with nuclear features similar to human PTC and gene expression changes conserved in human PTCs and predictive of improved disease free survival.

We have taken advantage of the optical clarity of zebrafish larvae to examine the earliest manifestations of oncogenic BRAF^V600E^ activity in vivo. Expression of BRAF^V600E^ leads to a disruption of follicle structure and thyroid hormone synthesis in zebrafish. Our findings are consistent with prior studies performed in cell culture using rat thyrocytes that demonstrated increased invasion and expression of markers consistent with EMT after expression of BRAF^V600E^ ([@bib29]). In a mouse model of PTC expression of BRAF^V600E^ led to the development of poorly differentiated carcinomas associated with activation of EMT ([@bib16]). Studies in human thyroid cancer cell lines in vitro also demonstrate that expression of BRAF^V600E^ induces SNAIL, represses E-CADHERIN, and leads to increased invasion ([@bib2]). Gene expression studies of human papillary thyroid cancer have identified increased expression of key EMT effectors in the invasive front of tumors ([@bib32]). BRAF^V600E^ has been found to physically interact and activate p21-activated kinase 1 (PAK1), a serine/threonine kinase involved in promoting migration in human thyroid cancer cell lines ([@bib22]). Our data significantly extend these studies and reveal that epithelial organization and thyroid hormone production is disrupted in vivo after expression of BRAF^V600E^. In contrast to a transgenic mouse models that develops aggressive poorly-differentiated thyroid carcinomas, our zebrafish model develops relatively slow growing thyroid cancer similar to the majority of human patients with PTC that grow slowly over many years. This has allowed us to dissect early vs. late effects of BRAF signaling on thyrocytes during malignant transformation. Future studies may take advantage of this latency to test candidate genes identified in cancer genomic studies ([@bib17]), and examine novel pathways that cooperate with BRAF^V600E^ to accelerate tumor initiation and progression.

We tested the effects of small molecule kinase inhibitors, clinically used for treatment of patients with *BRAF^V600E^* mutant tumors, using chemical-genetic approaches in transgenic zebrafish larvae. We find that treatment with either dabrafenib (a BRAF^V600E^ inhibitor) or selumetinib (a MEK inhibitor) alone is insufficient to suppress the morphologic phenotypes induced by oncogenic BRAF^V600E^ in zebrafish thyrocytes, but combined therapy with both agents suppresses oncogenic signaling and restores normal morphology. Similarly, in a *BRAF*-mutant ATC mouse model, the combination of PLX4720, a BRAF inhibitor and PD0325901, a MAPK kinase inhibitor, was more potent in suppressing MAPK activation than either agent alone ([@bib23]). Clinical studies with these agents in *BRAF^V600E^-*mutant melanomas also confirm that combined therapy has greater anti-tumor efficacy in human patients ([@bib20]). Multiple pathways that mediate resistance to BRAF inhibitors have been characterized in melanoma and colorectal carcinoma ([@bib28]). Our findings lead us to speculate that combined therapy with BRAF and MEK inhibitors may be required for treatment of *BRAF^V600E^* mutant thyroid carcinoma. This hypothesis is being tested in an ongoing clinical trial examining BRAF inhibition alone versus the combination of BRAF inhibition and MEK inhibition (ClinicalTrials.gov identifier NCT01723202).

Prolonged expression of BRAF^V600E^ leads to an invasive thyroid carcinoma with diagnostic features of human papillary thyroid carcinoma in adult zebrafish. Gene expression studies from tumors isolated from adult animals reveal signatures of proliferation and alterations in mTOR signaling during progression. In a mouse model of thyroid cancer genetic inactivation of TSH receptor attenuated tumor initiation suggesting that TSHR signaling cooperates with oncogenic BRAF ([@bib9]). We suggest that zebrafish thyroid carcinomas may arise slowly due to a relative euthyroid state that does not provoke elevated TSH levels, as seen in mouse models. Alternatively, it is possible that additional genetic alterations may be required for development of carcinoma. Thyroid cancers in zebrafish exhibit similar histologic features to human papillary thyroid cancer. These are relatively slow growing carcinomas that invade local tissues and exhibit a desmoplastic stromal reaction. Key diagnostic features of PTC, such as nuclear grooves and elongation, are observed, indicating conservation of these phenotypes across broad evolutionary distance. Interestingly tumor formation in zebrafish thyroid occurs on a tp53 wild-type background, in contrast to a zebrafish melanoma model in which tp53 loss of function is required for tumor formation ([@bib26]). These results confirm the importance of cellular context in modulating tumor initiation, consistent with genetic studies from human patients, which demonstrate BRAF mutations in papillary microcarcinomas ([@bib18]), the earliest pathologic lesions identified.

By studying the gene expression changes induced by BRAF^V600E^, we found enrichment of TGF-β/EMT signatures and a correlation with TWIST2 expression in human papillary thyroid carcinomas. TWIST proteins are over-expressed in a significant fraction of thyroid cancers ([@bib33]) and knockdown of TWIST1 in thyroid cancer cell lines led to a reduction in proliferation and migration ([@bib30]). We find that *twist3*, an orthologue of *TWIST2,* is significantly upregulated in thyrocytes upon *BRAF^V600E^* expression. Using CRISPR/Cas9 gene editing we find that genetic inactivation of *twist3* suppressed the effects of oncogenic BRAF^V600E^ in thyrocyte follicle structure and hormone synthesis. To our knowledge, these are the first in vivo data demonstrating a genetic requirement for TWIST expression downstream of BRAF^V600E^ in a thyroid cancer model.

Materials and methods {#s4}
=====================

Generation of constructs {#s4-1}
------------------------

All vectors were created using Gateway recombination (Life Technologies, Carlsbad, CA). A human *BRAF^V600E^* middle entry clone was made by PCR amplification as previously described ([@bib4]). pME-*BRAF^V600E^*, and pME-*TdTomato*, were used in LR reactions with pDestTol2pA, p3E-polyA and p5E-*tg* (containing a 514 bp of zebrafish thyroglobulin promoter fragment, as described ([@bib24]) to generate pTol2*tg:TdTomato-polyA,* pTol2*tg:EGFP-polyA*, and pTol2*tg:hBRAFV600E-polyA.*

Generation of zebrafish transgenic line {#s4-2}
---------------------------------------

Twenty-five picograms of pTol2tg:TdTomato-pA and 25 pg mRNA encoding the Tol2 transposase were injected into one-cell stage wild type AB larvae to create Tg(*tg:TdTomato-pA)* transgenic line. F1 TdTomato-positive animals were raised to adulthood and crossed to wild type fish. To create Tg*(tg:BRAF^V600E^-pA;tg:TdTomato-pA*) line, transgenic founders (F~0~) were generated by co-injecting 25 pg pTol2tg:TdTomato-pA with 25 pg pToltg:BRAF^V600E^-pA and 25 pg mRNA encoding the Tol2 transposase. Injected larvae were raised to adulthood and crossed to wild type fish for transgenic screening. F~1~ animals were raised to adulthood and genotyped for the presence of *BRAF* via PCR. Identification of transgenic Tg*(tg:BRAF^V600E^-pA;tg:TdTomato-pA*) line was performed using PCR-based amplification of *BRAF* in F2 TdTomato-positive larvae. To simplify nomenclature, we refer to larvae/adult Tg(*tg:TdTomato-pA)*, Tg*(tg:BRAF^V600E^-pA;tg:TdTomato-pA*) as tg-TOM, and tg-BRAF^V600E^-TOM, respectively.

Genotyping {#s4-3}
----------

Adult zebrafish were anesthetized with 0.004% MS-222 (Tricaine) (Western Chemical, Ferndale, WA), fin clipped and tissue was incubated in 150 μl of PCR lysis solution containing 20 μg/ml Proteinase K (Qiagen, Hilden, Germany) at 55°C for 60 min and followed by 45 min at 85°C. At the end of the incubation, lysates were centrifuged at 3000 rpm for 5 min and 100 μl were transferred to a new tube. One μl was used in a 10 μl PCR reaction using primers listed in [Supplementary file 1](#SD5-data){ref-type="supplementary-material"}.

Cell counting {#s4-4}
-------------

Five-day-old larvae were sacrificed and fixed in 4% PFA ON at 4°C washed in PBS containing 0.1% Tween 20 (PBST), treated with 50 µg/ml proteinase K (Roche, Basel, Switzerland) for 35 min and incubated with Sytox Green Nucleic Acid stain (1:1000, Thermo Fisher Scientific, Waltham, MA) for 1 hr at RT. Larvae were washed with PBST and post-fixed in 4% PFA for 20 min. After several washes with PBST, larvae were mounted in agarose. Z stacks were acquired on a confocal microscope and green-stained nuclei of TdTomato-positive cells were counted in three-dimensional (3D) image stacks using Imaris software (Bitplane, Concord, MA).

BrdU incorporation {#s4-5}
------------------

Three-day-old embryos were incubated in E3 fish water containing 10 mM BrdU (Sigma, St Louis, MO) and 15% DMSO for 20 min at 4°C. Medium was replaced with fresh E3 and embryos were incubated for 2 days at 28°C. Larvae were fixed in 4% PFA for 2 hr at RT, treated with 50 µg/ml proteinase K (Roche, Basel, Switzerland) for 35 min, post-fixed in 4% PFA for 20 min and incubated in 2N HCl for 1 hr. HCl solution was then removed and larvae were incubated in 0.1M Borate buffer, pH 8.5 for 20 min at RT. After several washes in PBT, larvae were incubated with blocking buffer and anti-BrdU antibody (1:200, Sigma, St Louis, MO) as described in Immunofluorescence.

Inhibitor treatment {#s4-6}
-------------------

Larvae were incubated at 18-somite stage in a 1 mL E3 medium containing 0.5% DMSO in a 24-well plate in the presence of the following inhibitors: 2.5 μM Dabrafenib (Selleckchem, Houston, TX), 10 μM Selumetinib (Selleckchem, Houston, TX) or a combination of the two inhibitors. These were the maximal tolerated doses compatible with normal development.

Imaging {#s4-7}
-------

Micrographs of whole larvae and adult fish were acquired with a Zeiss Discovery V8 stereomicroscope (Zeiss, Oberkochen, Germany) equipped with epifluorescence and appropriate filters. Live imaging of fluorescence larvae was acquired with a Zeiss LS510 laser scanning confocal microscope (Zeiss, Oberkochen, Germany). Images were further analyzed for detailed quantitative 3D analysis using Imaris software (BitPlane, Concord, MA). Brightfield images of adult fish were captured using a Canon EOS60D camera (Canon, Tokyo, Japan).

Sample preparation and histopathology {#s4-8}
-------------------------------------

Five (n = 5 and n = 10 tg-TOM and tg-BRAF^V600E^-TOM, respectively) or 12-month old (n = 5 and n = 14 tg-TOM and tg-BRAF^V600E^-TOM, respectively) animals were sacrificed and fixed in 4% PFA at 4°C for 3 days, followed by 3 days of decalcification in EDTA 0.5 M pH 8. After dehydration in 70% ethanol and processing using an automatic tissue processor, samples were embedded in paraffin and 5 μm sections were mounted on slides and stained with H&E for histopathologic examination. H&E-stained slides were reviewed with a board certified human pathologist specializing in the diagnosis of thyroid cancer (TS). The specific histopathologic features were reviewed and validated in comparison with normal thyroid specimens.

RNA extraction {#s4-9}
--------------

Twelve-month-old animals were sacrificed, and TdTomato-positive thyroid tissue was dissected under a stereomicroscope and placed in 500 µL Trizol (Life Technology, Carlsbad, CA). After homogenization, 100 μL of chloroform was added, and the samples were centrifuged at 12,000 x g for 15 min at 4°C. After centrifugation, the aqueous phase was transferred to a new tube, 300 μl of 70% ethanol was added and purified using an RNeasy Mini spin column (Qiagen, Hilden, Germany) as described by the manufacturer, including DNAse treatment (Qiagen, Hilden, Germany).

Western blot {#s4-10}
------------

Five-month-old animals were sacrificed and TdTomato-positive thyroid tissue was dissected under a stereomicroscope and homogenized in 40 µl RIPA buffer (Pierce, Waltham, MA). Five µg of total extract was resolved by SDS-PAGE, transferred to nitrocellulose and probed with the following antibodies: Phospho-p44/42 (1:1000, Cell Signaling, Danvers, MA), p44/42 (1:1000, Cell Signaling, Danvers, MA), thyroglobulin (1:20000, Dako, Glostrup, Denmark).

Immunohistochemical analysis {#s4-11}
----------------------------

Sections were deparaffinized with xylene and washed with ethanol followed by antigen retrieval using the following conditions: H~2~O~2~ at pH 9 at 100°C for 20 min. All immunostains were performed on the Bond III Autostainer (Leica Biosystem, Wetzlar, Germany) using the Bond Polymer Refine Detection kit (Leica Biosystem, Wetzlar, Germany) using the following conditions: blocking for 10 min, anti-TG antibody 1:2000 (Dako, Glostrup, Denmark), anti-PCNA 1:1000 (Sigma, St. Louis, MO) or anti-P-ERK 1:1000 (Cell Signaling, Danvers, MA) for 15 min. Slides were incubated in post primary AP for 8 min, followed by incubation for 8 min in Polymer AP. Slides were incubated with DAB for 10 min, counter stained with hematoxylin for 5 min and scanned using Aperio slide scanner (Leica, Wetzlar, Germany).

Immunofluorescence {#s4-12}
------------------

For anti-T4 immunofluorescence, 5-day-old larvae were fixed in 4% PFA overnight at 4°C. They were then washed in PBS containing 0.1% Tween 20 (PBST), treated with 50 µg/ml proteinase K (Roche) for 35 min and post-fixed in 4% PFA for 20 min. After several washes in PBST, larvae were incubated in blocking buffer (PBST containing 1.0% DMSO, 5% goat serum, and 0.8% Triton X-100) for 2 hr at RT, followed by overnight incubation in with anti-T4 antibody (1:2000, MP Biochemical, Solon, OH). After three washes in PBST containing 1% BSA, larvae were incubated with Alexa Fluor 488-conjugated anti-rabbit IgG secondary antibody for 3 hr at RT (1:500; Invitrogen, Carlsbad, CA). Stained larvae were washed in PBST and embedded in 1% low melt agarose for confocal imaging. For anti-E-Cadherin staining 5-day-old larvae were frozen and embedded in OCT (Sakura Finetek, Torrance, CA). Larvae were sectioned at 10 μM on a cryotome and sections were stained with anti-E-cadherin (1:500, Abcam, Cambridge, MA), followed by anti-mouse Alexa Fluor 488.

Embryo dissociation and fluorescence activated cell sorting {#s4-13}
-----------------------------------------------------------

Sixty 5 dpf larvae (in triplicate for each transgenic line, tg-TOM and tg-BRAF^V600E^-TOM) were sacrificed, de-yolked using calcium-free ringer solution, transferred to a 60 ml culture dish containing 4 ml of protease solution (0.25% trypsin, 1 mM EDTA) and incubated at 28°C for 30 min. The reaction was stopped with 100 µl 100 mM CaCl~2~ and 500 µl FBS. Cells were centrifuged for 3 min at 3000 rpm and resuspended in 5 ml of suspension medium (Colorless Leibovitz L-15, 0.8 mM CaCl~2~, penicillin/streptomycin and 1% FBS), centrifuged for 3 min at 3000 rpm, resuspended in 5 ml suspension medium and homogenized with a 10 ml pipette. Twenty U/ml of RNAse inhibitor (Life Technologies, Carlsbad, CA) was added, and the cell suspension passed through a cell strainer tube (BD Bioscience, San Jose, CA). TdTomato-positive cells were sorted using BD FACS Vantage SE with DiVa upgrade cell sorter (Becton, Dickinson and Co., San Jose, CA). For excitation of TdTomato fluorescent protein, 514 nm wavelength of Ar-Kr-ion laser with 200 mW power was used and fluorescence was detected in logarithmic mode via a BP575/26 nm optical filter. TdTomato-positive and negative cells were collected in 250 μl RLT buffer (Qiagen, Hilden, Germany) and nucleic acids were extracted. RNA extraction was performed using an RNeasy Micro Kit (Qiagen, Hilden, Germany) and subjected to DNAse treatment (Qiagen, Hilden, Germany). DNA extraction for clonal analysis of CRISPR/Cas9 activity was performed with an AllPrep DNA/RNA Kit (Qiagen, Hilden, Germany). The quality and the concentration of nucleic acids were assessed using a Bioanalyzer (Agilent, Santa Clara, CA). The RNA samples used in the study had a RIN between 7.4 and 9.4.

Amplification-library preparation and RNA-seq {#s4-14}
---------------------------------------------

One ng of RNA from three biological replicates of sorted cells for each transgenic line tg-TOM and tg-BRAF^V600E^-TOM was used to prepare amplified ds cDNA using Ovation RNA-Seq System V2 (Nugen, San Carlos, CA). Amplified ds cDNA was purified using QIAquick PCR purification kit (Qiagen, Hilden, Germany) and 200 ng of amplified cDNA was fragmented in a final volume of 50 µl using S220 Focused-ultrasonicator (Covaris, Woburn, MA), to obtain 150 bp DNA fragment size (peak incident power: 175W, duty factor: 10%, cycles per burst: 200, time: 280s). Fragmented DNA samples were used to prepare the library using TruSeq RNA sample preparation kit v2 (Illumina, San Diego, CA). For qPCR validation cDNA was diluted 1:7 and 2 µl were used in a 10 µl reaction using the PerfeCTa SYBR Green FastMix (Quanta Biosciences, Gaithersburg, MD). *Gapdh* was used as a control gene for normalization. Relative gene expression among samples was determined using the delta*C*~t~ method (2 -- ΔΔ*C*~t~). Results are expressed as the mean ± SEM in relative expression. For the library preparation of RNA derived from adult animals, RNA was extracted from dissected thyroid tissues as described and 100 ng from three tg-TOM and five tg-BRAF^V600E^-TOM biological replicates was used to prepare the library using TruSeq RNA sample preparation kit v2 (Invitrogen, San Diego CA). After validation using an Agilent DNA 1000 LabChip (Agilent, Santa Clara, CA), samples were submitted for RNA-seq.

CRISPR/Cas9 experiments {#s4-15}
-----------------------

Gene editing of *twist3* was performed by microinjection of 500 pg recombinant S. pyogenes Cas9 (PNA Bio, Thousand Oaks, CA) complexed with 1 µg synthetic sgRNA (ALT-R, Integrated DNA Technologies, Coralville IA). Ribonucleotide-protein complex formation was performed in vitro as described ([@bib38]). DNA was extracted from single injected embryos at 24hpf for analysis of indels. The targeted locus in *twist3* was PCR amplified using primers listed in [Supplementary file 1](#SD5-data){ref-type="supplementary-material"} and subject to TA cloning in pcr2.1 (Invitrogen). Plasmid DNA was isolated from individual clones and Sanger sequencing was performed. CRISPR/Cas9 gene editing was analyzed using CrispRVariants ([@bib19]). A T7 Endonuclease I (T7EI) assay was performed using 8 μl of PCR product in 20 [µ]{.ul}l final reaction containing 2U of T7EI (NEB, Ipswich, MA) for 1 hr at 37°C. Products were analyzed on a 1% agarose gel.

Bioinformatic analyses {#s4-16}
----------------------

Paired end reads were aligned using Star v2.3 ([@bib8]) to the zebrafish genome (GRCz10) using the Ensembl transcriptome ([@bib12]). Analysis of differential gene expression was performed using DESeq2 ([@bib21]). To identify differentially regulated genes between samples, we selected genes with log2 fold change greater than 1.2 or less than −1.2 and an adjusted p-value\<0.05. Orthology to human genes was determined using Ensembl ([@bib7]) and supplemented by performing BLAST ([@bib1]). GSEA ([@bib31]) was performed on RNAseq data using normalized counts and queried against the Hallmark in Cancer signatures from the MSigDB (<http://www.broadinstitute.org/gsea/msigdb/index.jsp>). Signatures represented in the results are the top 10, FDR \< 25%, nominal p-value\<5%. For the analysis of disease-free survival in human patients with PTC, we used clinical data from the TCGA PTC cohort ([@bib3]). We utilized the adult BRAF^V600E^ signature (n = 58 genes, [Figure 6D](#fig6){ref-type="fig"} and [Figure 6---source data 2](#SD3-data){ref-type="supplementary-material"}) to rank genes in the TCGA PTC samples using normalized RNAseq gene expression with a minimum rank method to resolve ties. We calculated the mean rank for the set of signature genes for each subject to estimate the overall regulation of the signature with respect to overall gene expression. We stratified subjects by median rank of the signature and performed a Kaplan-Meier survival analysis using disease free survival as the primary outcome. For the in silico screen to identify transcription factors associated with BRAF^V600E^ gene expression signatures, we utilized normalized gene expression from 496 TCGA PTC samples described ([@bib3]). We performed iterative GSEA against all transcription factors to identify enrichment with a BRAF^V600E^ signature identified in larval thyrocytes ([Figure 7---source data 1](#SD4-data){ref-type="supplementary-material"}).

Zebrafish husbandry {#s4-17}
-------------------

Zebrafish were bred and reared according to established guidelines ([@bib35]). All studies were performed in compliance with a protocol approved by our Institutional Animal Care and Use Committee (IACUC).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Oncogenic BRAF Disrupts Thyroid Morphogenesis and Function via Twist Expression\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Michael R. Green as the Reviewing Editor and Kevin Struhl as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Leonard I Zon, Craig Ceol.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Papillary Thyroid Cancers (PTC) can present as aggressive tumors (characterized by poorly differentiated cells) or indolent tumors (well-differentiated cells). Existing mouse models of PTCs depict the aggressive version of the disease. In this manuscript, the authors have developed a zebrafish model for PTC that closely mimics slow growing human PTCs. Zebrafish with thryocyte-specific expression of BRAFV600E have disrupted thyroid follicle structure and hormone synthesis during development. These transgenic zebrafish, upon adulthood, develop PTCs. The timing of tumor onset, histopathology and gene expression signature of these tumors recapitulate that of slow-growing human PTCs. The authors have demonstrated that the expression profile of these tumors is predictive of disease-free survival in patients with PTCs. CRISPR/Cas9-mediated targeting of twist3 (ortholog of human TWIST2) in BRAFV600E-expressing zebrafish thyrocytes restored thyroid structure and hormone producing ability. The authors have identified twist3 as a key downstream effector of BRAFV600E induced EMT in thyrocytes and claim that this process is essential in the early oncogenic transformation that initiates these cancers.

The manuscript describes a new zebrafish model of PTC that may be the best existing representation of slow-growing human PTC. The zebrafish model of PTC may serve a useful tool for stratifying PTC patients based on disease recurrence. Experiments are performed in a logical order and the manuscript is nicely written.

Essential revisions:

1\) Given that low degree of detected mutations (19%) and of these only 2 show loss of function (2/46 = 4%) in the cohort sequenced, it is surprising that the twist3 sgRNA causes such a dramatic reversal of phenotype. It is possible that the sequencing method used is underestimating the number of loss of function alleles. Please assess twist protein levels either through western or immunostaining at any time point to confirm significant loss of function of twist3. Alternatively, it the thyroid cells could be sorted at day 5 dpf after imaging and these cells could be sequenced via Next Generation Sequencing to assay the mutation rate. In addition, a negative control gRNA should be injected to ensure that injection of gRNA alone is not affecting the phenotype, especially given the discordance between the alleles predicted to be loss of function and the strong suppression of BRAF-related thyroid dysmorphic changes.

2\) The authors have used tissue-specific knockout of twist3 to claim that it is necessary for BRAF^V600E^-induced morphological changes in thyroid structure. Embryos injected with twist3 sgRNA ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) have morphological defects, notably cyclopia, that are reminiscent of general RNA toxicity. The authors should show that the rescue of thyroid structure is not due to non-specific morphological changes caused by RNA toxicity. A variety of control experiments can be performed to exclude this possibility.

3\) The Abstract asserts that the data demonstrate a genetic requirement for TWIST2 in the earliest step of BRAF^V600E^ transformation. Please rewrite this sentence with a more limited and specific conclusion. Alternatively, if data is already collected regarding whether twist3 CRISPR suppressed onset of BRAF-driven adult thyroid cancer in this model and if existing human sequencing data suggest this could be an early event in PTC development, please add these two lines of data.

4\) There are instances where the authors should fortify the claims they are making. First, in the Abstract it is stated that there is a \'genetic requirement for TWIST2 in the earliest step of BRAF^V600E^-mediated transformation\'. While twist3 might be important for BRAF^V600E^-driven changes in thyroid morphology, it is not clear that these morphological changes represent an early stage or step of oncogenic transformation. It would bolster their case if the authors show an effect of twist3 loss on BRAF^V600E^-driven tumorigenesis. Can they show that animals with thyroid-specific loss of twist3 also have delayed tumor onset? If not, then the authors\' claims should be rephrased. Second, the sentence \'We identify an orthologue of human TWIST2, twist3, as a key mediator of BRAF^V600E^ induced EMT in thyrocytes\' has similar issues. While an EMT signature (among others) is seen in BRAF^V600E^-expressing thyrocytes, the authors should do more before unequivocally stating this is EMT. Showing changes in expression of canonical EMT markers (e.g. E cadherin, N cadherin) is necessary.

5\) All three reviewers also agree that the authors have not done the experiments to be able to conclude that there is a \"pivotal functional role for TWIST expression during the earliest stage of malignant transformation by oncogenic BRAF\". The conclusions should be softened in the text. The work would form the basis of a nice new paper. To support this conclusion the authors would need to do a variety of human sequencing and cell culture work. We feel that all these experiments are clearly beyond the two-month time limit recommended by *eLife*. For example, sequencing of human PTCs for early events would be a whole other collaboration/project and cell culture work may not recapitulate the indolent nature of human PTC modeled in this paper and could take a long time, may up to a year. Given the time restraints suggested by *eLife*, we are comfortable instead having the authors remove the sentence at the end of the Discussion.

Non-essential revisions:

1\) One deficiency of the current manuscript is lack of human disease equivalent for the presented results. If available, please add data using human samples of thyroid cancer or thyroid cancer cell lines that this pathway is important, conserved and relevant to human thyroid cancer driven by BRAF^V600E^.

2\) The authors show that the effect of BRAF^V600E^ in thyroid morphogenesis can be rescued by combined treatment with BRAF and MEK inhibitors but not by either of them individually. The authors do not explain any further why this happens. Have the authors tried higher concentrations with individual inhibitors to see if they can show rescue?

3\) This is not necessarily a \'concern\', but could the authors determine whether their zebrafish PTC signature aligns more closely with human (or mouse) PTC versus PDTC. If the zebrafish signature is more similar to PTCs, then it would help their argument that they are modeling a more indolent form of the disease.

4\) The western blots in [Figure 4E](#fig4){ref-type="fig"} should be quantified as the changes are subtle.

5\) The histology images in [Figure 5](#fig5){ref-type="fig"} are difficult to see. Zoomed in insets of certain important regions/features within the PTC will help in visualizing these.

6\) The chromatograms in [Figure 7D](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1G](#fig7s1){ref-type="fig"} show wide peaks in mutated regions of the twist3 gene. In the clonal analyses described, where only one copy of the gene is being sequenced, regular-width peaks along with a commensurate frameshift downstream of the indel would be expected. It is not clear why the chromatograms look like they do.

7\) Please describe in the text how was the gene signature used in the data presented in [Figure 6](#fig6){ref-type="fig"} chosen. Did this gene signature predict improved OS for patients with PTC? If not, please hypothesize regarding any discrepancy.

8\) Please comment in the text or Discussion why in [Figure 2D](#fig2){ref-type="fig"} selemetinib decreases number of follicles significantly.

9\) [Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"} and the text associated with them would be clarified by addressing the following items.

a\) What is the significance if the pathologic features shown in [Figure 5](#fig5){ref-type="fig"} in human PTC if any?

b\) Please describe in the text whether the one-year animals get metastases.

c\) Were the animals with the desmoplastic reaction the same animals with the other pathologic features?

d\) If the animals look different at 12m with the tumors as compared to 5 mpf, can a photo of 12mpf fish with thyroid cancer be included at the beginning of [Figure 5](#fig5){ref-type="fig"}?

e\) Please also include more up close photos of the cytologic features in [Figure 5](#fig5){ref-type="fig"}, especially of the nuclear grooves and elongated nuclei so these can be appreciated.

f\) Please also annotate the structures being invaded in histologic structures in [Figure 4](#fig4){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"} to ensure non-zebrafish audience can appreciate the data.

10\) The manuscript would benefit from several small edits in order to clarify the work. Most of these edits will help the work be more accessible to a non-zebrafish audience.

Text edits:

Abstract: Please clarify that developmental effects of BRAF^V600E^-driven changes in thyroids were reversed with drug treatment.

Introduction, second paragraph: Please define the acronym NIS.

Subsection "BRAF^V600E^ expression leads to TGF-β and EMT gene expression changes in thyrocytes": Please name the tumors that the cell lines were derived from (thyroid?) and clarify how an ERK signature is derived by inhibiting MEK. Alternatively, simplify the sentence.

Subsection "BRAF^V600E^ expression leads to TGF-β and EMT gene expression changes in thyrocytes": Please clarify which of these groups of upregulated genes were also seen in the human data.

Subsection "BRAF^V600E^ expression in thyrocytes induces thyroid cancer in adult zebrafish": "We analyzed a second cohort of tg-BRAF^V600E^-TOM adult animals at 12 mpf and found evidence of progressive disease and histologic and cytological features consistent with thyroid carcinoma ([Figure 5](#fig5){ref-type="fig"}).": This sentence is redundant with the following sentence, please remove or combine with the following sentence. Or clarify the point being made.

Subsection "BRAF^V600E^ expression in thyrocytes induces thyroid cancer in adult zebrafish": The last sentence is also redundant, please remove this sentence or clarify if a different point was meant to be conveyed.

Subsection "Gene expression analysis of thyroid carcinoma reveals pathways involved in cancer progression and a gene expression signature predictive of disease free survival": Please rewrite the section title to more accurately describe the data. Consider: \"Gene expression analysis of zebrafish thyroid carcinoma reveals pathways involved in disease progression and the same gene signature in human PTC predicts increased disease free survival\".

Discussion, first paragraph: please change the word \"conserved\" to \"found\" as conserved implies an ancestral relationship.

Discussion, third paragraph: Please acknowledge that A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma. Clinical Trial -- NCT01723202 has been open to patient enrollment since 2012.

Discussion, fourth paragraph: -- Please clarify how BRAF being able to drive PTCs in adult zebrafish is consistent with BRAF mutations being identified in papillary microcarcinomas. Are BRAF mutations in thyroids observed in benign lesions as they are in nevi? Are no other genetic lesions seen in papillary microcarcinomas -- unless these two items are known please rephrase this sentence.

[Figure 4B](#fig4){ref-type="fig"} legend: positive is spelled incorrectly.

Regarding [Figure 6](#fig6){ref-type="fig"} in the text, please comment/discuss that RNA-seq data could also be different due to other cell populations being present in the sequenced sample as sorting was not done in this experiment.

11\) Figure edits:

[Figure 1D and 1E](#fig1){ref-type="fig"}: Add arrows in merge panel.

[Figure 4](#fig4){ref-type="fig"}: Please outline the fish on the fluorescent panel on 4A and 4B so the fluorescent signal on B can be appreciated anatomically.

Panel 6A: Please increase the font size of the red genes -- they are too small to read.

[Figure 7E](#fig7){ref-type="fig"}: Please align the panels.

[Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}: Please define either in to the legend or in the figure that the middle embryos are the ones injected with gRNA and recombinant Cas9 (so the whole embryo is affected). It is hard to tell from the figure the difference between the embryos seen in the middle and embryos on the R side as this figure is currently organized.

10.7554/eLife.20728.020

Author response

*Essential revisions:*

*1) Given that low degree of detected mutations (19%) and of these only 2 show loss of function (2/46 = 4%) in the cohort sequenced, it is surprising that the twist3 sgRNA causes such a dramatic reversal of phenotype. It is possible that the sequencing method used is underestimating the number of loss of function alleles. Please assess twist protein levels either through western or immunostaining at any time point to confirm significant loss of function of twist3. Alternatively, it the thyroid cells could be sorted at day 5 dpf after imaging and these cells could be sequenced via Next Generation Sequencing to assay the mutation rate. In addition, a negative control gRNA should be injected to ensure that injection of gRNA alone is not affecting the phenotype, especially given the discordance between the alleles predicted to be loss of function and the strong suppression of BRAF-related thyroid dysmorphic changes.*

In the revised manuscript we present new experimental data to address this point. We were not able to identify an antibody that recognizes zebrafish twist3 by immunohistochemistry. Therefore, we performed molecular studies using twist3 sgRNA and an assessment of mutation rate, as suggested.

We utilized a new synthetic sgRNA targeting *twist3* and compared this to a non- targeting sgRNA in embryos injected with rCas9. Utilizing a synthetic sgRNA we find no effect on early embryo development or morphogenesis, in contrast to our initial data using in vitrosynthesized sgRNA. This data prompted us to modify our approach and perform global CRISPR/Cas9 editing using recombinant Cas9, followed by analysis of follicle structure, T4 hormone production, and FACS of thyroid cells followed by a clonal analysis of editing in the *twist3* gene.

A clonal analysis of embryos injected with an sgRNA targeting twist3 shows that 16/21 (76%) clones harbor a range of indels at the targeted site, all predicted to lead to premature stop codon in twist3 (revised [Figure 7B](#fig7){ref-type="fig"}). We demonstrate that a non-targeting sgRNA produces no indels at the targeted site in 21 clones from 5 embryos ([Figure 7B](#fig7){ref-type="fig"}), and is also negative by T7 endonuclease assay. CRISPR/Cas9 editing of twist3 suppressed the thyroid phenotype in Tg-BRAF(V600E)-TOM embryos in 32% of larvae. Thus using new reagents we demonstrate that 1) CRISPR editing of twist3 suppresses the BRAF(V600E) phenotype on thyroid follicles, and restores T4 production, 2) the new molecular tools have high specificity for twist3, and 3) a non-targeting sgRNA does not produce molecular alterations in twist3 locus or revert the BRAF(V600E) phenotype. Finally, we performed FACS sorting of thyrocytes, as suggested, and a clonal analysis from these cells revealed indels in twist3 in 1/12 (8%) clones, confirming the presence of a twist3 loss of function mutation in thyrocytes. We acknowledge that the rate of indels in sorted thyrocytes (8%) is lower than observed in globally edited embryos (76%). It is possible that sorting low cell numbers and subsequent PCR amplification introduces bias and leads to an underestimate in the true rate of indels in sorted TOM+ cells. Nevertheless, we do confirm editing at a measurable rate in FACS sorted thyroid cells from embryos with a suppressed phenotype, and no edits were found in TOM+ cells sorted from non-target sgRNA injected animals, so we believe that the claim that we make is reasonable.

*2) The authors have used tissue-specific knockout of twist3 to claim that it is necessary for BRAF^V600E^-induced morphological changes in thyroid structure. Embryos injected with twist3 sgRNA ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) have morphological defects, notably cyclopia, that are reminiscent of general RNA toxicity. The authors should show that the rescue of thyroid structure is not due to non-specific morphological changes caused by RNA toxicity. A variety of control experiments can be performed to exclude this possibility.*

This comment led us to examine alternative sgRNAs to determine if they may be less toxic. Using a synthetic twist3 sgRNA we see no evidence of developmental toxicity, representative embryos at 5dpf are presented in [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}. Based on this finding we shifted our strategy to perform a global edit of twist3 in the tg-BRAF- TOM transgenic larvae, followed by analysis of follicle structure, hormone production, and FACS isolation of TOM+ thyrocytes from twist3 sgRNA or non-targeting sgRNA injected embryos. These experiments form the basis of a revised [Figure 7](#fig7){ref-type="fig"}.

*3) The Abstract asserts that the data demonstrate a genetic requirement for TWIST2 in the earliest step of BRAF^V600E^ transformation. Please rewrite this sentence with a more limited and specific conclusion. Alternatively, if data is already collected regarding whether twist3 CRISPR suppressed onset of BRAF-driven adult thyroid cancer in this model and if existing human sequencing data suggest this could be an early event in PTC development, please add these two lines of data.*

We have edited the sentence in the Abstract to present a more limited and specific conclusion. The sentence now reads, "These data suggest that expression of TWIST2 plays a role in an early step of BRAF^V600E^-mediated transformation."

*4) There are instances where the authors should fortify the claims they are making. First, in the Abstract it is stated that there is a \'genetic requirement for TWIST2 in the earliest step of BRAF^V600E^-mediated transformation\'. While twist3 might be important for BRAF^V600E^-driven changes in thyroid morphology, it is not clear that these morphological changes represent an early stage or step of oncogenic transformation. It would bolster their case if the authors show an effect of twist3 loss on BRAF^V600E^-driven tumorigenesis. Can they show that animals with thyroid-specific loss of twist3 also have delayed tumor onset? If not, then the authors\' claims should be rephrased. Second, the sentence \'We identify an orthologue of human TWIST2, twist3, as a key mediator of BRAF^V600E^ induced EMT in thyrocytes\' has similar issues. While an EMT signature (among others) is seen in BRAF^V600E^-expressing thyrocytes, the authors should do more before unequivocally stating this is EMT. Showing changes in expression of canonical EMT markers (e.g. E cadherin, N cadherin) is necessary.*

We have rephrased the sentence in the Abstract as noted above to present a more limited conclusion. Experiments to address the effects of twist3 loss of function on tumor development are ongoing and beyond the scope of the current manuscript. We agree that the connection between the early morphologic phenotypes and long term effects on tumor development is an important topic for future study.

We present new data to demonstrate a loss of E-cadherin staining in BRAF(V600E) expressing thyrocytes, consistent with EMT. This data is presented in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.

*5) All three reviewers also agree that the authors have not done the experiments to be able to conclude that there is a \"pivotal functional role for TWIST expression during the earliest stage of malignant transformation by oncogenic BRAF\". The conclusions should be softened in the text. The work would form the basis of a nice new paper. To support this conclusion the authors would need to do a variety of human sequencing and cell culture work. We feel that all these experiments are clearly beyond the two-month time limit recommended by eLife. For example, sequencing of human PTCs for early events would be a whole other collaboration/project and cell culture work may not recapitulate the indolent nature of human PTC modeled in this paper and could take a long time, may up to a year. Given the time restraints suggested by eLife, we are comfortable instead having the authors remove the sentence at the end of the Discussion.*

We have removed the sentence highlighted by the reviewers.

*Non-essential revisions:*

*1) One deficiency of the current manuscript is lack of human disease equivalent for the presented results. If available, please add data using human samples of thyroid cancer or thyroid cancer cell lines that this pathway is important, conserved and relevant to human thyroid cancer driven by BRAF^V600E^.*

In our manuscript we highlighted work showing that BRAF promotes invasion of thyroid cancer cells through an EMT and Snail dependent mechanism (Baquero, et al). We also discuss work demonstrating that TWIST is associated with lymph node metastasis in papillary thyroid carcinoma (Wang, et al), and that it modulates phenotypes in anaplastic thyroid cancer (Salerno et al).

In order to add more context to the significance of EMT in thyroid cancer we have added a reference (Vasko et al.) to a key publication that provided molecular evidence for an upregulation of EMT effectors at the invasive front in human papillary thyroid cancers.

*2) The authors show that the effect of BRAF^V600E^ in thyroid morphogenesis can be rescued by combined treatment with BRAF and MEK inhibitors but not by either of them individually. The authors do not explain any further why this happens. Have the authors tried higher concentrations with individual inhibitors to see if they can show rescue?*

The data we present represent the highest concentration of the inhibitors that is consistent with normal development. Higher concentrations resulted in severe developmental abnormalities that precluded analysis of effects on thyroid structure.

*3) This is not necessarily a \'concern\', but could the authors determine whether their zebrafish PTC signature aligns more closely with human (or mouse) PTC versus PDTC. If the zebrafish signature is more similar to PTCs, then it would help their argument that they are modeling a more indolent form of the disease.*

We agree that a comparison of PTC vs. PDTC may be informative. Unfortunately, the sample size of the publicly available PDTC gene expression datasets (n=17 PDTC samples in GEO GSE76039), makes it very challenging to perform a meaningful comparison.

*4) The western blots in [Figure 4E](#fig4){ref-type="fig"} should be quantified as the changes are subtle.*

As suggested we performed this analysis and include it in a revised [Figure 4F](#fig4){ref-type="fig"}.

*5) The histology images in [Figure 5](#fig5){ref-type="fig"} are difficult to see. Zoomed in insets of certain important regions/features within the PTC will help in visualizing these.*

As suggested we have provided zoomed insets to better visualize key histopathologic features, such as skeletal muscle invasion.

*6) The chromatograms in [Figure 7D](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1G](#fig7s1){ref-type="fig"} show wide peaks in mutated regions of the twist3 gene. In the clonal analyses described, where only one copy of the gene is being sequenced, regular-width peaks along with a commensurate frameshift downstream of the indel would be expected. It is not clear why the chromatograms look like they do.*

In the revised manuscript these specific chromatograms have been removed. A new chromatogram included in [Figure 7F](#fig7){ref-type="fig"} shows a 3 nucleotide indel, and the peak width is unchanged in the deleted region.

*7) Please describe in the text how was the gene signature used in the data presented in [Figure 6](#fig6){ref-type="fig"} chosen. Did this gene signature predict improved OS for patients with PTC? If not, please hypothesize regarding any discrepancy.*

As we described in the Materials and methods section and the [Figure 6](#fig6){ref-type="fig"} legend, we identified the top differentially expressed genes using standard metrics (FDR ≤ 1x10^-6^, FC ≤1.5). This resulted in a very stringent selection of 58 genes differentially regulated in BRAF thyroid tumors compared to normal thyroid tissue. In order to test whether these genes stratify a clinically meaningful outcome, such as disease free survival (DFS), we utilized RNAseq data from the TCGA papillary thyroid cancer cohort. As described in Materials and methods we calculated a rank per subject for the signature in the TCGA cohort. We then stratified subjects by median rank and performed an analysis of DFS. Almost no deaths occurred in the TCGA PTC cohort, which is typical for PTC, so an analysis of overall survival is not possible. We edited the Materials and methods section to improve clarity.

*8) Please comment in the text or Discussion why in [Figure 2D](#fig2){ref-type="fig"} selemetinib decreases number of follicles significantly.*

We have commented in the text that MAPK inhibition results in a modest decrease in follicle number, consistent with a proliferative requirement in follicle morphogenesis.

*9) [Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"} and the text associated with them would be clarified by addressing the following items.*

*a) What is the significance if the pathologic features shown in [Figure 5](#fig5){ref-type="fig"} in human PTC if any?*

We have edited the text to note that the features highlighted in [Figure 5](#fig5){ref-type="fig"} are diagnostic of thyroid carcinoma.

*b) Please describe in the text whether the one-year animals get metastases.*

We did not perform an exhaustive histologic study for distant metastatic disease instead focusing on local invasion. In fact, it is difficult to exclude metastasis as a mechanism for some of the disease we see in soft tissue and skeletal muscle.

*c) Were the animals with the desmoplastic reaction the same animals with the other pathologic features?*

These animals were distinct.

*d) If the animals look different at 12m with the tumors as compared to 5 mpf, can a photo of 12mpf fish with thyroid cancer be included at the beginning of [Figure 5](#fig5){ref-type="fig"}?*

The animals have a similar external appearance at 5mpf and 12mpf.

*e) Please also include more up close photos of the cytologic features in [Figure 5](#fig5){ref-type="fig"}, especially of the nuclear grooves and elongated nuclei so these can be appreciated.*

We improved the resolution of this figure to allow better appreciation of these features.

*f) Please also annotate the structures being invaded in histologic structures in [Figure 4](#fig4){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"} to ensure non-zebrafish audience can appreciate the data.*

We have provided insets to highlight skeletal muscle invasion.

*10) The manuscript would benefit from several small edits in order to clarify the work. Most of these edits will help the work be more accessible to a non-zebrafish audience.*

*Text edits:*

*Abstract: Please clarify that developmental effects of BRAF^V600E^-driven changes in thyroids were reversed with drug treatment.*

We edited the Abstract to address this point.

*Introduction, second paragraph: Please define the acronym NIS.*

We edited the text to address this point.

*Subsection "BRAF^V600E^ expression leads to TGF-β and EMT gene expression changes in thyrocytes": Please name the tumors that the cell lines were derived from (thyroid?) and clarify how an ERK signature is derived by inhibiting MEK. Alternatively, simplify the sentence.*

The ERK signature we utilize was derived from an analysis of BRAF(V600E) mutant melanoma and colon cancer cell lines (Pratilas, et al). In the Pratilas manuscript the authors examine genes that change in expression 8h after treatment with a MEK inhibitor. We have simplified the sentence in the text to avoid confusion.

*Subsection "BRAF^V600E^ expression leads to TGF-β and EMT gene expression changes in thyrocytes": Please clarify which of these groups of upregulated genes were also seen in the human data.*

GSEA analysis presents the genes that are most associated with a positive enrichment as hash marks on the left side of the plot. There is variability in how GSEA results are presented in the scientific literature. We do not feel that a complete listing of the GSEA results would add significantly to the manuscript.

*Subsection "BRAF^V600E^ expression in thyrocytes induces thyroid cancer in adult zebrafish": "We analyzed a second cohort of tg-BRAF^V600E^-TOM adult animals at 12 mpf and found evidence of progressive disease and histologic and cytological features consistent with thyroid carcinoma ([Figure 5](#fig5){ref-type="fig"}).": This sentence is redundant with the following sentence, please remove or combine with the following sentence. Or clarify the point being made.*

We edited the text to address this point, the sentences were combined.

*Subsection "BRAF^V600E^ expression in thyrocytes induces thyroid cancer in adult zebrafish": The last sentence is also redundant, please remove this sentence or clarify if a different point was meant to be conveyed.*

We edited an earlier sentence to avoid redundancy.

*Subsection "Gene expression analysis of thyroid carcinoma reveals pathways involved in cancer progression and a gene expression signature predictive of disease free survival": Please rewrite the section title to more accurately describe the data. Consider: \"Gene expression analysis of zebrafish thyroid carcinoma reveals pathways involved in disease progression and the same gene signature in human PTC predicts increased disease free survival\".*

We have edited the section title to address this point. The revised title reads: "Gene expression analysis of zebrafish thyroid carcinoma reveals pathways involved in disease progression and a gene expression signature that is predictive of disease free survival in human PTC".

*Discussion, first paragraph: please change the word \"conserved\" to \"found\" as conserved implies an ancestral relationship.*

We edited the text to address this point.

*Discussion, third paragraph: Please acknowledge that A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma. Clinical Trial -- NCT01723202 has been open to patient enrollment since 2012.*

We acknowledge this trial in the manuscript as suggested.

*Discussion, fourth paragraph: Please clarify how BRAF being able to drive PTCs in adult zebrafish is consistent with BRAF mutations being identified in papillary microcarcinomas. Are BRAF mutations in thyroids observed in benign lesions as they are in nevi? Are no other genetic lesions seen in papillary microcarcinomas -- unless these two items are known please rephrase this sentence.*

There are no known benign lesions harboring a BRAF(V600E) mutation in thyroid cancer, so the presence of a BRAF(V600E) mutation even in a microscopic specimen is diagnostic of cancer. BRAF(V600E) mutations are the most common somatic alteration in papillary thyroid cancer. For this reason, we feel that the comparison to papillary microcarcinoma is reasonable.

*[Figure 4B](#fig4){ref-type="fig"} legend: positive is spelled incorrectly.*

We corrected this misspelling.

*Regarding [Figure 6](#fig6){ref-type="fig"} in the text, please comment/discuss that RNA-seq data could also be different due to other cell populations being present in the sequenced sample as sorting was not done in this experiment.*

We feel that the manuscript contains sufficient methodologic detail as we state that Tomato+ tissue was microdissected. While we cannot exclude the possibility that there is contaminating tissue, the gross specimens submitted were homogenous by examination under a dissecting scope using epifluorescence, suggesting to us to that the tissue is almost entirely thyroid in origin.

*11) Figure edits:*

*[Figure 1D and 1E](#fig1){ref-type="fig"}: Add arrows in merge panel.*

The figure has been edited to address this point.

*[Figure 4](#fig4){ref-type="fig"}: Please outline the fish on the fluorescent panel on 4A and 4B so the fluorescent signal on B can be appreciated anatomically.*

We adjusted the contrast to better allow visualization of the location of the TOM+ thyroid in the ventral jaw and added an arrow to identify the site of fluorescence.

*Panel 6A: Please increase the font size of the red genes -- they are too small to read.*

[Figure 6A](#fig6){ref-type="fig"} has no gene names called out, so we are uncertain of the query.

*[Figure 7E](#fig7){ref-type="fig"}: Please align the panels.*

This figure has been revised.

*[Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}: Please define either in to the legend or in the figure that the middle embryos are the ones injected with gRNA and recombinant Cas9 (so the whole embryo is affected). It is hard to tell from the figure the difference between the embryos seen in the middle and embryos on the R side as this figure is currently organized.*

This figure has been revised.
